CytoMed Therapeutics Limited (GDTC)

USD 2.37

(-6.32%)

Market Cap (In USD)

27.34 Million

Revenue (In USD)

384.74 Thousand

Net Income (In USD)

-3.13 Million

Avg. Volume

66.93 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.2-5.5
PE
-
EPS
-
Beta Value
0.66926515
ISIN
SGXZ17669631
CUSIP
-
CIK
1873093
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Wee Kiat Tan Ph.D.
Employee Count
-
Website
https://w2.cytomed.sg
Ipo Date
2023-04-14
Details
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.